Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin

Leukemia Research

Volumn 33, Issue 8, 2009, Pages 1096-1099

  Morris, Karen L ^a   Adams, Julie A ^a   Liu Yin, John A ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Acute myeloid leukaemia; Cloretazine; VNP40101M

Indexed keywords

CLORETAZINE; CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; BLAST CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MALE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTARABINE; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDRAZINES; LEUKEMIA, MYELOID, ACUTE; SULFONAMIDES;

EID: 67349176354     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.01.025     Document Type: Article

References (9)

1. Finch R.A., Shyam K., Penketh P.G., and Sartorelli AC. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Research 61 (2001) 3033-3038
2. Mao J., Xu Y., Wu D., and Almassain B. Pharmacokinetics, mass balance, and tissue distribution of a novel DNA alkylating agent, VNP40101M, in rat. AAPS PharmSci 4 (2002) E24
3. Zheng L.M., Li Z., Liu L., Song B.L., and King I. Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models. Cancer Chemotherapy and Pharmacology 60 (2007) 45-51
4. Adams D.J., Sandvold M.L., Myhren F., Jacobsen T.F., Giles F., and Rizzieri DA. Anti proliferative activity of ELACYT™ (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukaemia and lymphoma cells. Leukemia and Lymphoma 49 (2008) 786-797
5. Murren J., Modiano M., Kummar S., Clairmont C., Egorin M., Chu E., et al. A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer. Invest New Drugs 23 (2005) 123-135
6. Giles F., Thomas D., Garcia-Manero G., Faderl S., Cortes J., Verstovsek S., et al. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clinical Cancer Research 10 (2004) 2908-2917
7. Giles F., Verstovsek S., Faderl S., Vey N., Karp J., Roboz G., et al. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukaemia. Leukaemia Research 30 (2006) 1591-1595
8. Giles F., Verstovsek S., Thomas D., Gerson S., Cortes J., Faderl S., et al. A phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukaemia. Clinical Cancer Research 11 (2005) 7817-7824
9. Giles F., Rizzieri D., Karp J., Vey N., Ravandi F., Faderl S., et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukaemia. Journal of Clinical Oncology 25 (2007) 25-31